angina with non-obstructive coronary arteries

in review 5 min read Updated 2026-10-19
angina with non-obstructive coronary arteries

Angina (or equivalent) with no stenosis ≥50% — up to half of patients sent for angiography; younger, fewer risk factors, more often women than obstructive CAD. A working diagnosis: coronary function testing finds a cause in 75–90% — microvascular dysfunction, microvascular or epicardial spasm, endothelial dysfunction, or a myocardial bridge, often more than one. A normal stress test does not exclude it; don’t label it non-cardiac until tested. Troponin rise with the same angiogram → MINOCA.

endotypes

endotypemechanismdefinition on testing
coronary microvascular dysfunction (CMD)structural remodelling, rarefaction, impaired endothelium-independent dilationadenosine: CFR <2.0–2.5 and/or IMR ≥25 (hMR ≥2–2.5 by Doppler)
endothelial dysfunction↓ NO release → ACh constricts instead of dilatingACh: epicardial constriction >0% to ≤90%, or coronary flow ↑ <50%
microvascular spasmmicrovascular smooth-muscle hyperreactivityACh: usual pain + ischaemic ECG, no epicardial spasm
epicardial spasm (vasospastic angina)large-artery hyperreactivityACh: >90% constriction + usual pain + ischaemic ECG
myocardial bridgingsystolic compression of an intramyocardial segment; consider in all — angiography insensitiveIVUS halo / >10% compression; significant if dobutamine diastolic FFR, iFR or RFR ≤0.76
  • CFR grey zone 2.0–2.4. Low CFR + high IMR = classic CMD, highest event risk; isolated low CFR (high resting flow) and isolated high IMR are distinct, less certain endotypes.
  • CFR <2 by any modality → ↑ death and CV events, graded with severity.
  • Epicardial spasm → ↑ MI and repeat angiography; microvascular spasm → recurrent angina. Overall prognosis of spasm favourable.

workup

  • Non-invasive: PET myocardial blood flow reserve is the most accurate and prognostically validated (stress CMR perfusion and TTE Doppler LAD flow in select centres). AHA/ACC 2021 chest pain guideline: PET or stress CMR flow reserve 2a; invasive testing 2a if at least mild ischaemia on imaging.
  • CCTA: non-invasive gold standard for myocardial bridge anatomy (length, depth); not physiology.
  • Invasive coronary function testing (one sitting, LAD by default):
    • adenosine + pressure/thermodilution wire → CFR, IMR
    • ACh 20 µg slow (endothelial function) → 100 µg bolus (spasm); 200 µg optional (men, high suspicion); RCA ≤50 µg
    • IVUS for bridging ± dobutamine physiology
    • hold caffeine, nitrates, beta-blockers, CCBs, ACEi/ARB ≥24 h; avoid radial CCB “cocktail” (masks spasm); ≥6-lead ECG; nitroglycerin to reverse spasm
  • Safety: major complications 0.5%, minor 4.4% (mostly transient AV block/bradycardia — pause ACh; AF usually self-limited); no deaths. No routine temporary pacing unless RCA tested.

vasospastic angina

COVADIS criteriondetail
1. nitrate-responsive angina (spontaneous) + ≥1 ofrest angina (night–early morning); morning ↓ exercise tolerance; hyperventilation-provoked; suppressed by CCB, not beta-blocker
2. transient ischaemic ECG change (≥2 contiguous leads)ST elevation or depression ≥0.1 mV, or new negative U waves
3. coronary spasmtransient >90% constriction with angina + ischaemic ECG, spontaneous or provoked (ACh, ergonovine, hyperventilation) — all three, else equivocal
  • Definitive = 1 + (2 or 3). Suspected = 1 with 2 and 3 equivocal or unavailable. Prinzmetal (variant) angina = rest pain with transient ST elevation.
  • Provocation strongly indicated: ACS without culprit, unexplained resuscitated arrest, syncope preceded by chest pain, recurrent rest angina after successful PCI, suspicious history unresponsive to empiric therapy. Contraindicated: emergent ACS, severe multivessel/left main disease, severe LV dysfunction, no suggestive symptoms.
  • Invasive testing only — arrhythmia ~7%, no reported deaths; bedside non-invasive provocation has caused deaths.
  • Risk factor: smoking (not diabetes or hypertension). Triggers: cocaine, 5-FU, allergen (Kounis), phaeochromocytoma.

treatment by endotype

Few adequately powered RCTs; sequential start with uptitration every few weeks, tracking symptoms (CCS class, Seattle Angina Questionnaire).

endotypefirst linesecond / third linenotes
CMDbeta-blocker (vasodilating, e.g. nebivolol, may be preferable) + ACEi + statin ranolazine (benefit if CFR <2.5), L-arginine, ivabradine; third: nicorandil (Health Canada SAP); trimetazidine (limited, conflicting data)CCB benefit uncertain (diltiazem did not change CFR/IMR — EDIT-CMD); long-acting nitrate only if refractory
epicardial or microvascular spasm, endothelial dysfunctionCCB (DHP or non-DHP equally effective) + statin; SL nitroglycerin for episodesDHP + non-DHP together; long-acting nitrate (tolerance — nitrate-free interval); cilostazol, cyproheptadine; nicorandil (CCS 2024); refractory spasm → stellate ganglion blockbeta-blocker with caution (unopposed α → ↑ vasomotor tone); stop smoking, cocaine, trigger drugs (CCS 2024); diltiazem resolved epicardial spasm in 47% vs 6% (EDIT-CMD)
myocardial bridgingbeta-blocker; CCB alternativerefractory → surgical unroofingnitrates less effective (↑ systolic compression); stenting not advised (fracture, restenosis); CABG often fails (competitive flow)
  • All: exercise/cardiac rehab, weight loss, psychotherapy or meditation; TCA/SSRI if refractory (abnormal nociception); EECP or nerve stimulation for refractory angina; hormonal suppression if catamenial.
  • Statin for all ANOCA (recommended broadly; improves endothelial function).
  • Aspirin: no evidence of benefit in ANOCA, though commonly prescribed (observational link with more spasm) — give if atherosclerosis present.
  • Undifferentiated ANOCA → WARRIOR (ASA + high-intensity statin + max ACEi/ARB vs usual care) ongoing.
  • Women’s heart centres (BC, ON, QC, NS) for complex cases.

CorMicA (2018): ANOCA (n=151) → CFT found CMD 52%, spasm 17%, both 21%, none 11%; trial protocol stratified therapy to the result (CMD: ASA, statin, ACEi, beta-blocker → non-DHP CCB → DHP CCB/nicorandil/ranolazine; spasm: CCB + long-acting nitrate) ↑ angina and QoL at 1 year vs blinded usual care.

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction angina with non-obstructive coronary arteries